Modular Antibody Technology
Our robust discovery engine lets us easily “mix-and-match” antibody components to create unique bispecific antibody products.
F-star develops genuine monoclonal bispecific antibodies that can bind two different targets at the same time, for use as “2-in-1” drugs.
News & Events
- 9 January 2014: F-star creates asset-centric unit
- 10 December 2013: F-star appoints Tolga Hassan as Chief Financial Officer
- 23 October 2013: F-star announces formation of new asset-centric vehicle, F-star Alpha Ltd, with €9.4m Series A investment